Abstract
Corporate social responsibility (CSR) aimed at increasing access to medicines (ATM) has recently witnessed evolutionary and revolutionary changes, both at the conceptual and implementation levels. Indeed, with the global burden of disease shifting from acute to chronic diseases, the philanthropy based model of CSR that responds to short-term ATM needs becomes insufficient to mitigate ATM for chronic conditions. New CSR options, strategic to business revenues and therefore sustained by the private sector, could provide longer-term ATM solutions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Antoun J, Phillips F and Johnson T (2011). Post-Soviet Transition: Improving Health Services Delivery and Management. Mount Sinai Journal of Medicine 78 (3): 436–448.
Armendariz B and Morduch J (2004). MicroFinance: Where Do We Stand? Financial Development and Economic Growth: Explaining the Links, The Economics of Microfinance (Cambridge, MA: MIT Press).
The Basic Law of Saudi Arabia, Chapter 5, article 31. http://www.mideastinfo.com/documents/Saudi_Arabia_Basic_Law.htm
Brogan D and Mossialos E (2006). Applying the Concepts of Financial Options to Stimulate Vaccine Development. Nature Reviews: Drug Discovery 5: 641–647.
Cameron A, Ewen M, Ross-Degnan D, Ball D and Laing R (2009). Medicine Prices, Availability, and Affordability in 36 Developing and Middle-Income Countries: A Secondary Analysis. Lancet 373: 240–249.
Commission of the European Communities (2001). Green Paper Promoting a European framework for Corporate Social Responsibility, Com (2001) 366 final, Brussels, 18th July.
Commission of the European Communities (2002). Communication from the Commission concerning Corporate Social Responsibility: A Business Contribution To Sustainable Development, COM (2002) 347 final, Brussels, 2nd July.
Danzon P, Towse A and Mulcahy A (2011). Pharmaceutical Pricing in Rich and Poor Countries: Setting Cost-Effectiveness Thresholds as a Means to Achieve Appropriate Drug Pricing. Health Affairs 30 (8): 1529–1538.
Department for International Development (DFID) (2004). Increasing Access to Essential Medicines in the Developing World, London, UK.
Duffau A and Pedregal V (2009). To What Extent Does Non Profit Private Micro Health Insurance Help Improve Public Health Care? Field Actions Science Reports, 3. http://factsreports.revues.org/360, accessed 23 April 2012.
Friedman M (1970). The Social Responsibility of Business It to Increase its Profits. New York Times Magazine, September 13, 1970, 33, 126.
Gelders S, Ewen M, Noguchi N and Laing R (2005). Price, Availability, and Affordability: An International Comparison of Chronic Disease Medicines. Background Report Prepared for the WHO Planning Meeting on the Global Initiative for Treatment of Chronic Diseases, Cairo Egypt. World Health Organization and Health Action International; Cairo 2006.
GlaxoSmithKline Corporate Responsibility Report (2010). http://www.gsk.com/responsibility/cr-report-2010/access-to-medicines/future-plans/
Goroff M and Reich MR (2010). Partnerships to Provide Care and Medicine For Chronic Diseases: A Model For Emerging Markets. Health Affairs December 29:122206–122213.
Hale V, Woo K and Lipton HL (2005). Oxymoron No More: The Potential of Nonprofit Drug Companies to Deliver on the Promise of Medicines to the Developing World. Health Affairs 24(4): 1057–1063.
Hunt P (2007). Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines. Draft for consultation prepared by the UN Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.
Kanavos PL, Seeley E and Vandoros S (2009). Tender Systems for Outpatient Pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium. European Commission.
Kotler P and Lee N (2005). Corporate Social Responsibility: Doing the Most Good for Your Company and Your Cause (Hoboken, NJ: John Wiley and Sons).
Lee M and Kohler J (2010). Benchmarking and Transparency: Incentives for the Pharmaceutical Industry’s Corporate Social Responsibility. Journal of Business Ethics 95: 641–658.
Lichtenberg F (2003). The Impact of New Drug Launches on Longevity: Evi-dence from Longitudinal Disease-level Data from 52 Countries, 1982–2001. NBER Working Paper No. 9754.
Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Khatib O, et al. (2007). The Availability and Affordability of Selected Essential Medicines for Chronic Diseases in Six Low- and Middle-Income Countries. Bulletin of the World Health Organization 85 (4): 279–288.
Misra A and Khurana L (2008). Obesity and the Metabolic Syndrome in Developing Countries. The Journal of Clinical Endocrinology and Metabolism 93 (suppl. 1): S9–S30.
Philanthropist News Digest (PND) (2011). Ellen and Douglas Rosenberg Foundation Awards $3.5 Million for Alzheimer’s Drug Development. Febru-ary 4, 2011 accessed at: http://foundationcenter.org/pnd/news/story.jhtml?id= 325400003
Pollio G and Obuobie J (2010). Microfinance Default Rates in Ghana: Evi-dence from Individual-Liability Credit Contracts. Microfinance Information Exchange. http://www.themix.org/publications/microbanking-bulletin/2010/1 1/microfinance-default-rates-ghana-evidence-individual-liab
Popkin BM (2008). Will China’s Nutrition Transition Overwhelm Its Health Care System and Slow Economic Growth? Health Affairs July/August 27(4): 1064–1076. http://content.healthaffairs.org/cgi/reprint/27/4/1064.pdf
Roberts MJ, Hsiao W, Berman P and Reich MR (2004). Getting Health Reform Right: A Guide to Improving Performance and Equity (New York: Oxford University Press).
Roberts MJ and Reich MR (2002). Ethical Analysis in Public Health. The Lancet 359: 1055–1059.
Shaw B and Post F (1993). A Moral Basis for Corporate Philanthropy. Journal of Business Ethics 12 (10): 745–751.
Shaw JE, Sicree RA and Zimmet PZ (2009). Global Estimates of the Prevalence of Diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 87: 4–14.
Shepard Al (2010). Generic Medicines: Essential Contributors to the Long-Term Health of Society. IMS Health. http://www.imshealth.com/imshealth/Global/Content/Document/Market_Measurement_TL/Generic_Medicines_ GA.pdf
Sorenson C (2010). Use of Comparative Effectiveness Research in Drug Coverage and Pricing Decisions: A Six-Country Comparison (New York: The Commonwealth Fund).
The United Nations (UN) (2005). Prescription for Healthy Development: Increasing Access to Medicines. http://www.unmillenniumproject.org/documents/TF5-medicines-Complete.pdf
Wirtz V, Kaplan W, Téllez Y and Ridaura R (2011). Affordable, Quality, Long-Term Care and Pharmacotherapy of Chronic Diseases: A Framework for Low and Middle Income Countries. Report Commissioned by The Alliance for Health Policy and System Research. World Health Organization, Geneva.
World Business Council for Sustainable Development (WBCSD) (2002). The Business Case for Sustainable Development: Making a Difference Towards the Johannesburg Summit 2002 and Beyond. World Business Council for Sustainable Development, Geneva, Switzerland.
The World Health Organization (WHO) (2011). The World Medicines Situation: Medicines Prices, Availability and Affordability. http://www.who.int/medicines/areas/policy/world_medicines_situation/WMS_ch6_wPricing_ v6.pdf
The World Health Organization and Health Action International (WHO and HAI) (2007). Medicine Prices in Egypt; Unpublished Report submitted at the WHO/HAI Post-Medicine Price Survey Workshop. Cairo, Egypt.
Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J and Murray CJL (2003). Household Catastrophic Health Expenditure: A Multicountry Analysis. Lancet 362: 111–117.
Editor information
Editors and Affiliations
Copyright information
© 2012 the contributors
About this chapter
Cite this chapter
Antoun, J. (2012). CSR to Increase Access to Medicines: Lessons and Opportunities for the Middle East. In: Jamali, D., Sidani, Y. (eds) CSR in the Middle East. Palgrave Macmillan, London. https://doi.org/10.1057/9781137266200_4
Download citation
DOI: https://doi.org/10.1057/9781137266200_4
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-34541-0
Online ISBN: 978-1-137-26620-0
eBook Packages: Palgrave Business & Management CollectionBusiness and Management (R0)